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1. Introduction
Mitochondria are the organelles with the main 
responsibility for energy production in cells, generated 
in the form of ATP by oxidative phosphorylation 
(OXPHOS). Mitochondria are additionally involved in 
many other important processes, including apoptosis 
and calcium homeostasis (Pozzan et al., 2000; Newmeyer 
and Ferguson-Miller, 2003). Furthermore, mitochondria 
are the main site of the production of reactive oxygen 
species (ROS). The tricarboxylic acid (TCA) cycle, which 
in addition to its contribution to ATP production also 
generates several important metabolic intermediates, 
occurs in mitochondria (Boveris et al., 1972).
Mitochondria contain their own genetic material, called 
mitochondrial DNA (mtDNA), a 16,569-bp-long, double-
stranded, circular molecule containing just 37 genes. Only 
13 of these genes encode proteins, all of them contributing 
to the formation of OXPHOS complexes through 
association with nuclear DNA (nDNA)-encoded proteins. 
The remaining genes encode 22 tRNAs and 2 rRNAs 
(Anderson et al., 1981). The copy number of mtDNA varies 
depending on the cell type and energy demand of the tissue. 
Replication of mtDNA is dependent on proteins encoded by 
nDNA and imported to mitochondria. Therefore, mtDNA-
related diseases can be caused not only by mutations in 
mtDNA but also by defects in nDNA-encoded factors 
required for mtDNA replication (Figure 1). This dual-
dependence of mtDNA integrity is largely responsible for 
the heterogeneous nature of mtDNA-related diseases. 
The history of research on mtDNA-related diseases 
is relatively short, with the first disease-causing mtDNA 
mutations reported in 1988 (Holt et al., 1988; Wallace et al., 
1988). These two ground-breaking studies paved the way 
to the discovery and characterization of a large number of 
mtDNA mutations, and at least 300 pathogenic mtDNA 
mutations have now been identified (www.mitomap.org). 
Due to the high degree of heterogeneity in mtDNA-related 
diseases, it is very hard to quantify their prevalence. Studies 
have been conducted to define the severity of mtDNA 
mutations in specific populations; however, a worldwide 
study in this field is missing. A study based in northeastern 
England reported that mtDNA-related diseases occurred 
at a frequency of 1 in 10,000 in working-age adults with 
a further 1 in 6000 people (below retirement age) at 
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risk of developing these diseases (Schaefer et al., 2008). 
Subsequent reports have suggested that the frequency of 
mtDNA mutations is much higher (Greaves et al., 2012). 
Recent advances in molecular biology and sequencing 
techniques will inevitably lead to the characterization of 
new mtDNA mutations, which will help provide a more 
accurate estimate of the prevalence of these diseases, and 
thereby a better understanding of the impact of mtDNA-
related diseases on society.
The mechanisms underlying mtDNA-related disorders 
can explain why they are associated with such a high 
degree of clinical heterogeneity. The mechanistic details of 
mtDNA dysfunction need to be investigated in depth in 
order to design novel therapeutic strategies. This review 
examines the state of the art regarding these mechanisms 
and reviews some recent therapeutic advances in the field.
2. Features of mtDNA genetics 
2.1. The mtDNA molecule at a glance
The publication of the first sequence of human mtDNA 
in 1981 marked a milestone in mitochondrial research 
(Anderson et al., 1981). Our current understanding of 
the mtDNA sequence incorporates subsequent revisions 
(Andrews et al., 1999). The mtDNA molecule contains 
no introns and only a few noncoding bases (Anderson 
et al., 1981). The molecule is formed by a guanine-rich 
heavy strand (H) and a cytosine-rich light strand (L). The 
only noncoding region in mtDNA is called the D-loop 
(displacement loop) and it contains control elements 
required for mtDNA transcription and replication (Shadel 
and Clayton, 1997). Unlike the nuclear genome, which is 
found in 2 copies of 23 chromosomes (2n = 46), mtDNA 
can occur in multiple copy numbers. The maintenance of 
mtDNA copy number is discussed in a separate section.
mtDNA exists in protein-linked structures called 
nucleoids, compact macrocomplexes formed and 
stabilized principally through the action of mitochondrial 
transcription factor A (TFAM) (Kaufman et al., 2007). 
mtDNA nucleoid-associated proteins are a subject of 
intense research but as of yet there is no consensus on their 
characteristics or number (Hensen et al., 2014). Further 
advances in this area will provide a clearer picture on the 
role of nucleoid structure in mtDNA maintenance.
Maintenance and homeostasis of mtDNA is determined 
by various processes specialized for their function. In the 
following sections we review some of the key features of 
mtDNA in order to provide a better understanding of 
mtDNA-related diseases and their mechanisms. These 
features should be taken into account during diagnosis 
and treatment of mitochondrial disease patients.
2.2. Heteroplasmy and threshold
MtDNA accumulates mutations at a fast rate, leading to 
mitochondrial dysfunction. The inherent ROS formation 
associated with the OXPHOS system might be the primary 
cause of the accumulation of mutations in mtDNA (Brown 
et al., 1979). Nonmutated and mutated mtDNA copies can 
coexist in the same cell and even in the same mitochondria, 
a condition called heteroplasmy. MtDNA mutations can 
also be found in a homoplasmic state, when no nonmutated 
mtDNA copies are present. In the heteroplasmic state, 
the proportion of mutated mtDNA copies needs to 
pass a certain threshold in order to cause a pathological 
defect detectable by biochemical tests. However, there 
is no clear correlation between the heteroplasmy level 
and the clinical severity of disease (Wong, 2007), and 
the threshold level can vary depending on the mutation 
type, adding another level of complexity to the treatment 
of mtDNA-related disorders. A recent study showed that 
small changes in mtDNA heteroplasmy cause significant 
changes in the nDNA transcriptome (Picard et al., 2014). 
This transcriptional reprogramming upon mitochondrial 
dysfunction is also known as retrograde signaling and is 
activated by changes in ATP/AMP, NADH/NAD+, ROS, 
cytosolic Ca2+, and membrane potential. These changes 
are interpreted by the cells as signals of mitochondrial 
dysfunction. Retrograde signaling further causes changes 
in expression of genes involved in various signaling 
pathways (e.g., mTOR, Myc, NFKB), mitochondrial 
transcription, capacity, or biogenesis and usually causes a 
metabolic switch towards glycolysis. The interconnected 
complex mechanism of this phenomenon is the subject of 
a recent review by our group (Cagin and Enriquez, 2015).
2.3. Random segregation, mtDNA bottleneck, and clonal 
expansion
Mitochondrial segregation during cell division has been 
suggested to be random, which need to be investigated 
in deeper detail (Lombes et al., 2014). This suggests that 
the segregation of mitochondria carrying mutant and 
wild-type mtDNA will result in one daughter cell having 
more mutant mtDNA and the other having more wild-
type mtDNA. Random mitochondrial segregation would 
result in the production of daughter cells with varying 
proportions of putatively mutant mtDNA. If the mutant 
mtDNA proportion exceeds a certain threshold level, a 
biochemical defect will be evident. In contrast, in fast-
dividing cells this random segregation can result in rapid 
loss of mutant mtDNA, as has been observed in blood 
samples (Rahman et al., 2001). Furthermore, evidence 
from multiple studies suggests that a bottleneck during 
development results in rapid segregation of heteroplasmic 
mtDNA, providing another route to homoplasmy (Upholt 
and Dawid, 1977; Olivo et al., 1983; Holt et al., 1989; Vilkki 
et al., 1990; Blok et al., 1997; Cree et al., 2008b). However, 
the developmental phase at which the bottleneck occurs is 
not clearly defined and is debated. 
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A mosaic pattern of mtDNA is observed in COX-
deficient muscle fibers of patients with mitochondrial 
dysfunction. The suggested mechanism responsible for 
this is called clonal expansion, and it is due to random 
replication of mtDNA resulting in cells with differing 
proportions of mutant to wild-type mtDNA. This will 
result in loss of mutant mtDNA in some cells, providing 
protection for those specific cells. However, the cells 
that accumulate mutant mtDNA will over time develop 
biochemical defects. Clonal expansion also happens in 
postmitotic cells, explaining the accumulation of mutant 
mtDNA with aging in muscle cells and neurons (Greaves et 
al., 2012). The rapidly aging world population has generated 
great interest in the involvement of mitochondria in aging, 
and the mechanisms connecting mtDNA mechanisms 
to aging are central to understanding the exact roles of 
mitochondria in healthy aging.
2.4. Maternal inheritance
Unlike nDNA, mtDNA is transmitted to offspring 
uniparentally, in most animals from the mother (Giles et 
al., 1980). Maternal inheritance is widely accepted among 
researchers; however, some published data suggest that 
a limited degree of paternal inheritance can occur. For 
example, some studies have suggested paternal inheritance 
of a ND2 gene mutation (Schwartz and Vissing, 2002). The 
existence of a low level of paternal inheritance has been 
supported by subsequent studies and might account for 
some rare familial mtDNA diseases with no identified 
cause (Danan et al., 1999; Marchington et al., 2002; Filosto 
et al., 2003; Taylor et al., 2003b; Schwartz and Vissing, 
2004). However, maternal inheritance is far more likely 
and should be examined as the more likely option to track 
the familial history of the mutation.
3. Types and mechanisms of mtDNA dysfunction
3.1. Primary mutations 
MtDNA point mutations and deletions can be classified 
as primary mtDNA disorders (Figure 1). MtDNA point 
mutations can occur in mt-tRNA, mt-rRNA, or mt-
mRNA. The clinical symptoms of mtDNA point mutations 
Figure 1. nDNA and mtDNA mutations associated with mtDNA-related diseases. Mitochondria are surrounded by two membranes, 
as shown in the upper left image. MtDNA is located within the matrix. A continuously cross-talk between mitochondria and nuclei 
(upper right panel) is required for mitochondrial function. Mutations both in mtDNA and nDNA can result in mtDNA-related diseases. 
Schematic representations of types of nDNA and mtDNA mutations that result in mtDNA-related diseases are listed in the lower panels.
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are heterogeneous, and in some cases the same mutation 
can result in different symptoms. Most point mutations 
that result in a clinical phenotype occur in mt-tRNA and 
usually result in an overall reduction in mitochondrial 
protein synthesis (Mariotti et al., 1994). In contrast, mt-
mRNA mutations usually (but not always) result in specific 
respiratory complex defects (Figure 2). The disease-
causing heteroplasmy threshold can differ depending 
on the type of mutation, with mtDNA deletions usually 
having lower disease-causing threshold than mt-tRNA 
mutations (approximately 60% vs. 80%; Kirino et al., 2004; 
Taylor and Turnbull, 2005).
3.2. Point mutations 
In general, point mutations are heteroplasmic and highly 
recessive. However, there are reports of homoplasmic 
mtDNA point mutations affecting a single tissue and 
characterized by incomplete penetrance (McFarland 
et al., 2002; Taylor et al., 2003a; Temperley et al., 2003; 
McFarland et al., 2004; McFarland et al., 2007; Yang et al., 
2009). The three most common homoplasmic mutations, 
causing Leber’s hereditary optic neuropathy (LHON), 
are m.11778G > A, m.3460G > A, and m.14484T > C 
(McFarland et al., 2007). 
Here we focus on the three most common heteroplasmic 
mutations observed in patients. The commonest mt-
tRNA mutation is the m.3243A > G mutation on mt-
tRNALeu(UUR), first characterized in a subgroup of patients 
with mitochondrial encephalomyopathy, lactic acidosis, 
and stroke-like episodes (MELAS) (Goto et al., 1990). More 
recent studies reported that this mutation mostly results in 
maternally inherited diabetes and deafness (MIDD) (Nesbitt 
et al., 2013). The same study showed that this mutation can 
result in progressive external ophthalmoplegia (PEO) and 
that some affected individuals have overlapping symptoms 
(i.e. MELAS + MIDD, MELAS + PEO, MIDD + PEO). 
Furthermore, 9% of carriers show no clinical phenotype, 
and the high levels of heterogeneity makes diagnosis of the 
disease very challenging (Nesbitt et al., 2013).
Figure 2. Mechanisms of nDNA and mtDNA mutations associated with mtDNA-related diseases: mutations resulting in mtDNA-
related diseases can either occur on mtDNA or nuclear genome (left, blue panel). These mutations have multiple targets, which can affect 
various processes (middle, green panel). These can result in a single-complex or multiple-complex defect or mtDNA loss or a shift in 
heteroplasmy; in all cases, OXPHOS activity is disrupted (right, red panel).
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The second most common heteroplasmic point 
mutation is also on a tRNA gene. The m.8444A > G 
substitution in mt-tRNALys (Shoffner et al., 1990) mostly 
results in myoclonic epilepsy with ragged red fibers 
(MERFF) and is also linked to some cases of a MIDD-like 
syndrome (Santorelli et al., 1996a). Comparison of the 
m.32343A > G and m.8444A > G mutations highlights the 
clinical heterogeneity of mtDNA-related diseases, although 
both cause OXPHOS defects through a decreased protein 
synthesis rate (Yasukawa et al., 2000).
Clinically heterogeneous disease states also result from 
an amino acid substitution (Leu 156 Arg) in ATP synthase 
subunit 6, caused by the m.8993T > G mutation (Santorelli 
et al., 1996b). This mutation is mainly linked to two 
diseases: NARP (neuropathy, ataxia, retinitis pigmentosa) 
and MILS (maternally inherited Leigh’s syndrome). 
Interestingly, the mutation causes NARP at 90%–95% 
heteroplasmy and causes MILS at higher heteroplasmy 
rates (Tatuch et al., 1992).
3.3. Deletions
MtDNA deletions result from defects in mtDNA 
replication, maintenance, and repair (Kaukonen, 2000; 
Spelbrink et al., 2001). MtDNA deletions mostly occur 
between origins of replication (OH and OL) and regions 
flanked by tandem repeat sequences (Schon et al., 1989; 
Krishnan et al., 2008). Deletions are normally sporadic, 
occur in the germline, and are not transmitted to offspring 
(Chinnery et al., 2004). The size of large-scale mtDNA 
deletions varies, but many patients have a ~5-kb ‘common-
deletion’ that spans the ATPase8 and ND5 genes as 
represented in Figure 1 (Larsson and Holme, 1992).
The main determinants of clinical severity of a deletion 
seem to be its abundance and tissue distribution, rather 
than the size and location of the deletion itself (Tuppen 
et al., 2010). However, recent studies also suggest a 
correlation among deletion size, heteroplasmy, and clinical 
severity (Grady et al., 2014).
MtDNA deletions are frequently associated with three 
syndromes: Pearson syndrome, Kearns–Sayre syndrome 
(KSS), and chronic progressive external ophthalmoplegia 
(cPEO) (Zeviani et al., 1988; Moraes et al., 1989; Rotig 
et al., 1990). Moreover, many studies have shown that 
mtDNA deletions accumulate with aging and are mainly 
linked to nervous system disorders (Cortopassi et al., 1992; 
Bender et al., 2006; Kraytsberg et al., 2006). Increased 
levels of mtDNA deletions have been found in the brains of 
elderly individuals and in heart tissue affected by coronary 
atherosclerosis (Corral-Debrinski et al., 1992a, 1992b).
3.4. mtDNA copy number maintenance 
In addition to direct mutations in mtDNA, mtDNA 
dysfunction can also be caused by mutations in nDNA 
(Figure 1). MtDNA-related nuclear genes that cause 
disease mainly affect mtDNA replication and copy number 
maintenance, and they fall into two categories: those that 
directly affect the mtDNA replication fork and mutations 
in genes that are involved in the supply of nucleotides for 
mtDNA replication (such as mitochondrial thymidine 
kinase TK2, the deoxyguanosine kinase dGK, and adenine 
nucleotide transporter ANT1) (Copeland, 2008). The 
effects of these mutations are sometimes called secondary 
mtDNA defects. mtDNA copy number is regulated in 
accordance with the energy demand of the cell. Cells under 
a high energy demand, like muscle cells and neurons, thus 
need to maintain high numbers of healthy and functional 
mtDNA. This homeostasis can be disrupted either by 
increased replication of mtDNA or by targeted degradation 
of damaged mtDNA molecules (Szklarczyk et al., 2014). 
There is some supporting evidence that oxidative stress 
can increase mtDNA degradation (Shokolenko et al., 2009; 
Furda et al., 2012). 
Copy number maintenance is central to healthy 
aging. mtDNA copy number decreases with aging in 
different tissues, including pancreatic islets, skeletal 
muscle, cerebral cortex, and heart muscle (Frahm et 
al., 2005; Short et al., 2005; Cree et al., 2008a). Similar 
observations have been reported in model organisms, 
such as an age-related decrease in mtDNA copy number in 
the rat CNS (McInerny et al., 2009). However, the impact 
of mitochondrial dysfunction on aging varies between 
species such as mice and humans (Greaves et al., 2011). 
One study of two well-known mtDNA-related diseases, 
MELAS and MERRF, showed an aging-related reduction in 
mtDNA levels in leukocytes (Liu et al., 2006). Mutations in 
the OPA1 gene, whose function is to induce mitochondrial 
fragmentation, result in dominant optic atrophy (Alavi and 
Fuhrmann, 2013). There are conflicting results concerning 
whether this mutation results in mtDNA loss or mtDNA 
proliferation (Iommarini et al., 2012; Sitarz et al., 2012). 
Further work is needed to determine the mechanisms 
of mtDNA replication and their involvement in disease 
progression. 
The factors needed for mtDNA replication are 
completely encoded by nDNA. This adds another level 
of complexity to the maintenance of a healthy mtDNA 
population. MtDNA polymerase γ (Pol γ), a heterodimeric 
protein consisting of a catalytic subunit (PolgA) and a 
processivity subunit (polgB), is the exclusive mediator 
of mtDNA polymerase activity (Carrodeguas et al., 
2001). Mitochondrial DNA helicase, also called Twinkle, 
is responsible for 5’-3’ mtDNA helicase activity, and 
mitochondrial single-strand binding protein (mtSSB) is 
responsible for the stabilization of the single strand once 
the double strand is unwound (Spelbrink et al., 2001). 
Together with TFAM these proteins form the mitochondrial 
replisome, which can be reconstituted in vitro (Korhonen 
et al., 2004). The mechanism of mtDNA replication is 
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not fully defined. There are mainly two models: strand 
displacement and strand coupling (Clayton, 1982; Holt et 
al., 2000). Both models have been critically appraised, but 
a detailed description of this area is beyond the scope of 
this review (Bogenhagen and Clayton, 2003b, 2003a; Holt 
and Jacobs, 2003). Pol γ is one of the most widely studied 
nuclear genes involved in mtDNA disorders because of 
its high error rate of 1:50,000 bp (Longley et al., 2001). 
More than 150 mutations in Pol γ have been identified in 
patients with mtDNA disorders (Human DNA Pol Gamma 
Mutation Database, http://tools.niehs.nih.gov/polg/). 
These mutations can be found in all domains of Pol γ and 
can cause PEO, Alpers syndrome (Naviaux and Nguyen, 
2004), ataxia neuropathy (Van Goethem et al., 2004), and 
male infertility (Rovio et al., 2001). A detailed overview of 
Pol γ is available in the Human DNA Pol Gamma Mutation 
Database (http://tools.niehs.nih.gov/polg/).
3.5. mtDNA depletion syndrome
Loss of mtDNA in tissues is usually identified as mtDNA 
depletion syndrome (MDS). General clinical symptoms 
include muscle weakness, progressive encephalopathy, 
liver failure, and disturbed function of the skeletal muscle, 
kidneys, and brain (Rahman and Poulton, 2009). MDS 
was first characterized as an autosomal recessive disorder 
(Moraes et al., 1991) and is widely reported in childhood 
respiratory deficiency syndromes (Sarzi et al., 2007).
The genetic alterations leading to MDS commonly 
affect the mtDNA replication components (Pol γ, Twinkle, 
TFAM) (Spelbrink et al., 2001), but they can also involve 
genes required for the supply of sufficient dNTPs for 
mtDNA replication. dNTPs are supplied to mitochondria 
either by active transport of cytosolic dNTPs or through 
a salvage pathway that mainly requires TK2 (thymidine 
kinase 2) (Suomalainen and Isohanni, 2010). Mutations 
in TK2 have been reported as the most common cause of 
MDS (Saada et al., 2001). MDS can also be triggered by 
mutations in dGK (Mandel et al., 2001) or ribonucleotide 
reductase (Bornstein et al., 2008), and another 
enzyme important for maintaining the dNTP pool, TP 
(thymidine phosphorylase), causes the mtDNA-related 
disease MNGIE (mitochondrial neurogastrointestinal 
encephalomyopathy) (Nishino et al., 1999). 
4. Clinical, biochemical features, and diagnosis of 
mtDNA-related diseases
4.1. Clinical assessment and examination
The diagnosis of mtDNA-related diseases is quite complex, 
which should be extensive. The age of onset of mtDNA-
related diseases is variable and is determined primarily 
by the severity of the defect and the mutation load and 
to a lesser extent by environmental and nuclear genetic 
modifier factors. It is common to classify mtDNA-related 
diseases into two groups: ‘early infancy and childhood’ vs. 
‘late childhood and adulthood’. Leigh syndrome, mtDNA 
depletion syndromes, KSS, and Pearson syndrome fall 
into the first group, while mitochondrial encephalopathy, 
MELAS, cPEO, neuropathy, NARP, LHON, and 
MERRF are usually observed in late childhood and 
adulthood (Tuppen et al., 2010). The high degree of 
tissue heterogeneity is another hallmark of mtDNA-
related diseases. Neurological, gastrointestinal, cardiac, 
respiratory, endocrinal, ophthalmological, hematological, 
renal, muscular system, and liver failure are involved in 
mtDNA-related diseases (Vafai and Mootha, 2012). 
In order to assess the clinical situation of a patient, the 
clinician should carry out various tests on the possible 
organ systems that could be involved in the disease. 
One group of these tests is based on imaging. Cardiac 
failure can be investigated by electrocardiography 
(ECG), electromyography (EMG) can reveal muscular 
defects, and computed tomography (CT) and magnetic 
resonance imaging (MRI) findings can help to evaluate 
the patients’ condition (Menezes et al., 2014). Certain 
blood-based biochemical tests have shown promise as 
diagnostic tools for mitochondrial disorders. Measuring 
the level of lactate, pyruvate, creatine kinase, total blood 
count, thyroid and liver function, bone chemistry, and 
blood glucose levels can be informative (Naviaux, 2004). 
For example, it is common to observe high lactate and 
pyruvate levels in patients with mitochondrial disorders as 
a result of a compensatory mechanism to overcome ATP 
deficit; however, this is not always observed in LHON and 
KSS. Organic acids and amino acid profiles measured by 
chromatography, mass spectrometry, or HPLC can aid 
the observations. Although a clear correlation is missing, 
an increase in alanine, proline, glycine, sarcosine, and 
tyrosine can be observed in mtDNA-related diseases. In 
addition, novel biomarker discoveries are expected to help 
towards the diagnosis of mitochondrial disorders, thereby 
decreasing the diagnostic work currently required. So far, 
cytokine FGF-21 (fibroblast growth factor-21) has been 
found to be a biomarker for muscle-specific mitochondrial 
diseases (Suomalainen et al., 2011).
4.2. Histopathology
Regardless of the underlying mutation, all mtDNA-related 
disorders result in defects in oxidative phosphorylation 
as shown in Figure 2 (Betts et al., 2004). However, tissue 
heterogeneity and specificity remain the major reasons for 
the need of detailed analysis of mitochondrial function 
in different tissues, if possible. In order to carry out a 
more extensive assessment, a muscle biopsy is needed 
since this tissue mostly, but not always, shows a defect 
in most of the mtDNA-related diseases (Janssen et al., 
2003). Effective communication with the patient is needed 
at this stage in order to obtain a muscle biopsy sample 
together with a fibroblast sample, both of which can be 
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used for subsequent analysis. One of the most established 
techniques is the staining of the muscle fibers with Gomori 
trichrome, which results in ragged red fibers (RRFs), 
which reflect the abnormal subsarcolemmal accumulation 
of mitochondria (Tuppen et al., 2010). The most common 
and penetrant phenotype is COX (cytochrome c oxidase) 
deficiency, first reported in chronic PEO patients’ 
fibers (Johnson et al., 1983). COX/SDH (succinate 
dehydrogenase) immunohistochemical double-staining 
is commonly used to classify normal versus deficient cells 
in mitochondrial diseases. SDH staining shows a normal 
pattern in disorders caused only by mtDNA defects but 
not by nDNA (so-called primary mtDNA mutations), 
since all subunits of complex II are encoded by nDNA. 
Therefore, SDH staining can be mainly used to identify 
complex II defects. COX staining can result in a mosaic 
pattern, or in some cases, global and uniform decrease is 
observed. Mosaic COX deficiency highlights heteroplasmy 
differences; on the other hand, uniform COX defects 
are related to nDNA mutations mainly encoding COX 
subunits and assembly factors (e.g., SURF1, SCO2) (Zhu et 
al., 1998). It should also be noted that COX deficiency may 
be observed upon aging since there is an accumulation of 
mtDNA mutations by age (Brierley et al., 1998). Such cases 
should be classified in the context of aging rather than 
specific mtDNA-related diseases. Finally, more analysis 
can be made by measuring mitochondrial ultrastructure 
using electron microscopy and respiratory chain complex 
activities from isolated mitochondria; however, these also 
depend on the availability of the materials and resources. 
A more detailed explanation of clinical symptoms and 
histopathological findings was reviewed elsewhere (Taylor 
and Turnbull, 2005; Greaves et al., 2012).
4.3. DNA-based diagnosis
The detailed investigation of the family history of the 
patient may reveal the genetic defect of the individual 
and help to differentiate whether it is mtDNA or nDNA 
related, since mtDNA has a maternal inheritance. In detail, 
observation of mtDNA deletions usually reflects a defect in 
mtDNA maintenance genes (e.g., PolG, PEO1, OPA1) and 
mtDNA depletion reflects defective mtDNA replication 
related to the replication genes (PolG, mtSSBP, Twinkle, 
Tfam) or genes involved in the supply of the dNTP pool 
(TK2, dGK). In some cases, the clinical phenotypes may 
reflect a common mutation causing well-defined diseases 
such as MELAS (m.3243A>G) or MERRF (m.8344A>G). 
In such cases, a direct sequencing of the genetic location 
or RFLP can be applied. Additionally, the heteroplasmy 
levels of these mutations should be determined either by 
RFLP or TaqMan real-time PCR analysis. Furthermore, 
long-range PCR or real-time PCR can be used to detect 
the mtDNA deletions (He et al., 2002). These primary 
mtDNA defects were discussed in the earlier sections of 
this study. Furthermore, mtDNA depletion, caused by 
nDNA-encoded gene mutations (for details, see Section 
3), can be detected by real-time PCR. There are many 
cases where the disease-causing mutation on mtDNA has 
not been defined before. Direct sequencing of the whole 
mtDNA can provide much information. However, care 
should be taken while choosing the candidate mutation 
and a pathogenic disease causing mutation. The criteria for 
this were published by DiMauro and Schon and we refer 
their work for this purpose (DiMauro and Schon, 2001).
The improvements in sequencing technologies 
allowed the usage of next-generation sequencing (NGS) 
as a new way to diagnose mitochondrial diseases. Recent 
figures show that NGS allowed not only to assign already 
characterized mutations to patients but also to discover 
novel mutations (Menezes et al., 2014). Whole-genome 
sequencing (WGS) is still very expensive to be used on a 
daily basis, but whole-exome sequencing (WES) has been 
used commonly in recent years. Although intronic defects 
can be linked to some diseases, most genetic diseases are 
caused by mutations present in exons (coding regions), 
which correspond to less than 2% of the whole genome. By 
using WES, all of the variants in exons can be detected in a 
single experiment rather than in several sequencing runs. 
The difficulty in this is to assign a variant as a disease-
causing variant. Here, we refer to a recent review published 
by Suomalainen’s group for details and criteria of variant 
identification (Carroll et al., 2014). A more targeted 
approach for mitochondrial diseases can be taken by using 
MitoExome, which has been proven to detect both known 
and novel mutations causing mitochondrial diseases. 
Independent studies have shown that this methodology 
can be applied successfully (Calvo et al., 2012; Vasta et al., 
2012; Lieber et al., 2013). All these advances in sequencing 
resulted in characterizing around 50 novel mutations, 
although recent reports highlight that more improvements 
are needed. Two independent studies carried out at 
hospitals in Japan and the United States show that for 
around 50% of the WES cases, the functional pathogenic 
(disease-causing) variant could not be determined (Lieber 
et al., 2013; Ohtake et al., 2014). Better comparative analyses 
will be made possible by including more sequencing data 
of more cases (especially control for nonmitochondrial 
diseases). More reliable sequencing reactions are also 
needed together with efficient bioinformatics tools. In any 
case, assigning a highly probable variant (mutation) as a 
disease-causing variant remains a challenge. Therefore, 
functional studies on cells (depending on the availability) 
should be performed before making a decision about a 
causative DNA variant (Danhauser et al., 2011).
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5. Potential treatment strategies
5.1. Treatments to improve quality of life
Improving the quality of life of the patients should be the 
primary goal to be achieved right after the diagnosis. It has 
been shown that exercise therapy can help this; however, 
it neither stops nor prevents the occurrence of the disease. 
Aerobic training proved to improve OXPHOS activity and 
exercise capacity of patients with mitochondrial myopathy 
(Jeppesen et al., 2006). Furthermore, endurance exercise 
improved mitochondrial myopathy symptoms in a mouse 
model of the disease (Wenz et al., 2009). 
Controlled and optimized diet can also help to improve 
quality of life. A ketogenic diet, rich in fat and low in 
glucose, results in high amounts of mitochondrial beta-
oxidation and ketone body production, which has been 
shown to slow the progression of mitochondrial myopathy 
in mice (Ahola-Erkkila et al., 2010). Other multiple studies 
have shown various phenotypically beneficial effects such 
as reduction in epileptic seizures, improved brain energy 
metabolism, inhibition of ROS production, and increased 
neuroglia interaction and ATP concentrations (Khan et 
al., 2015). Furthermore, a ketogenic diet was found to 
decrease the level of deleted mtDNA copies, causing a shift 
in heteroplasmy, in cultured human cells (Santra et al., 
2004).
Most treatment strategies for mtDNA-related diseases 
follow the guidelines published by the Wellcome Trust 
Centre for Mitochondrial Research in Newcastle, UK 
(http://www.newcastle-mitochondria.com/service/
patient-care-guidelines/). The discovery of mtDNA 
mutations and progress in our understanding of disease 
mechanisms have paved the way toward potential cures 
for mtDNA-related diseases. Experimental animal models 
have been very informative in defining and tailoring 
treatment strategies. Animal models of mtDNA-related 
disorders are described in a number of valuable and 
detailed reviews (Oliveira et al., 2010; Palladino, 2010; 
Dogan and Trifunovic, 2011; Dunn et al., 2012). 
5.2. Pharmacological treatments
Potential therapeutic strategies are focused on the 
positive effects of pharmacological and biochemical 
agents observed in cellular and animal models. One of 
the frequently observed outcomes of mtDNA-related 
disorders is a change (usually an increase) in the level of 
oxidative stress. Mitochondria are a major producer of 
cellular ROS and multiple mtDNA mutations have been 
shown to result in increased ROS. The neurodegeneration 
phenotype observed in LHON patients was found to be 
caused by increased level of ROS. Creation of cybrid lines 
harboring 11,778 and 3460 mutations and subsequently 
differentiating them into neurons resulted in increased 
ROS (more in 3460 mutations); however, undifferentiated 
cells did not show any difference (Wong et al., 2002). 
Two NARP-causing mutations at the same location 
(m8993T>G and m8993T>C) are reported to cause 
increased ROS production and SOD activity (Baracca et 
al., 2007). It is worth further emphasizing that although 
these two mutations occur at the same location, the level 
of increase in ROS is different. Furthermore, increased 
ROS production was observed in different tissues (heart 
and brain) in a heteroplasmic mouse model harboring 
the commonly observed m3243A>G tRNA mutation (Li 
et al., 2008). In view of the focus of this special issue on 
‘Melatonin and Mitochondria Interact in Diseases’, we 
detail here some of the recent advances on the potentially 
beneficial effects of melatonin, and specifically mtDNA-
related disorders.
The hormone melatonin, secreted by the pineal gland, 
is a potent free-radical scavenger and regulates redox-
active enzymes (Galano et al., 2011). Melatonin is also 
regarded as a possible mitochondrial protector and can 
restore mitochondrial function in a mouse model of 
Alzheimer disease involving a transgenic mutant form of 
APP (amyloid precursor protein) (Dragicevic et al., 2011). 
More information related to the roles of melatonin in 
neurodegenerative process can be found in the literature 
(Pandi-Perumal et al., 2013). A recent study was carried 
out on NARP cybrids harboring 98% heteroplasmy in the 
m.8993T > G mutation, which is associated with a defect 
in F1F0-ATP synthase. Melatonin has been reported to 
have the potential to rescue heart function in patients after 
myocardial ischemia/reperfusion (Huang et al., 2013), a 
conclusion supported by similar studies (Peng et al., 2012). 
As explained earlier, the ~5-kb ‘common-deletion’ is 
widely observed in patients with mtDNA-related diseases. 
The increased mitochondrial ROS (mROS) production 
associated with the common deletion can be rescued by 
melatonin, preventing mROS-mediated depolarization of 
membrane potential (Jou et al., 2007).
Furthermore, the lifespan-extending effect of 
rapamycin (Bonawitz et al., 2007; Pan et al., 2012) has 
been shown to have a mtDNA origin (Villa-Cuesta et al., 
2014). This further highlights the complex dual control of 
mitochondrial homeostasis. Potential dietary therapeutic 
approaches have also explored the potential of alpha-
ketoglutarate/aspartate supplements (Sgarbi et al., 2009). 
Continuing research in this area will provide additional or 
complementary therapeutic opportunities.
Similar approaches have been used to study the potential 
benefits other metabolites and vitamins, etc. Frequently 
cocktails of various cofactors and vitamins are being used. 
The choice of these agents is usually made if the molecule 
under question is defective, less produced, or mutated or if 
its transport is being impaired. Here we summarize most 
of the molecules used for the treatment of mitochondrial 
diseases. Coenzyme Q10 (CoQ10, ubiquinone) is part 
of the electron transport chain and it is also a ROS 
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scavenger (Ernster and Dallner, 1995). CoQ10 deficiency 
is commonly observed in various different mitochondrial 
diseases and CoQ10 supplementation has been overall 
successful (Quinzii and Hirano, 2010). Riboflavin (water-
soluble vitamin B, B2) is a precursor of flavoprotein, which 
has key roles for complex I, complex II, the Krebs cycle, 
and fatty acid oxidation. Therefore, riboflavin is usually 
supplied in complex I and complex II diseases (Bernsen 
et al., 1993; Bugiani et al., 2006). Creatine is found at 
high concentrations in energy-demanding tissues such 
as the muscle and brain. It can be classified as an energy-
boosting compound since it forms phosphocreatine, 
which is a source of high-energy phosphate. It has been 
used in combination with CoQ10 (Dimauro and Rustin, 
2009). L-Arginine, which is a semiessential amino acid, 
has been successfully used for treatment of MELAS (Koga 
et al., 2002). Carnitine, which has a key role in fatty acid 
metabolism, is used to increase free carnitine levels and is 
usually used together with CoQ10 (Marriage et al., 2004). 
Dichloroacetate (DCA) is a lactic acid-lowering molecule 
that can be targeted to patients with increased lactate or 
lactic acidosis. However, a double-blinded MELAS study 
showed toxic effects of DCA, which resulted in decline of 
its use (Kaufmann et al., 2006). Idebenone is an analogue 
of CoQ and has been used in LHON patients with some 
degree of success (Carelli et al., 2011). Vitamins B1, C, and 
E and alpha-lipoic acid, dimethylglycine, and whey-based 
glycine are other molecules in use. For a detailed review 
of each of these molecules we refer to the very valuable 
work of others (Parikh et al., 2009; Kanabus et al., 2014). 
Compounds undergoing clinical trials between 1997 and 
2012 were also recently reviewed (Kerr, 2013).
There are other pharmacological agents present on the 
verge of clinical trials for the treatment of mitochondrial 
diseases. One group of such agents with promising 
outcomes are focused on increasing mitochondrial 
biogenesis via PGC1α, PPARs, NRF1/2, YY1, and ERRs 
(Andreux et al., 2013) . Bezafibrate, which is a synthetic 
ligand of PPARα, has been proposed to be a new 
pharmacological agent supported by several positive results 
obtained in mouse models (Kanabus et al., 2014). A clinical 
trial of bezafibrate in mitochondrial disorders is missing, 
although promising observations were made in a clinical 
trial of a fatty acid oxidation disorder called carnitine 
palmitoyl transferase 2 (CPT2) deficiency (Bonnefont 
et al., 2010). Another candidate targeting mitochondrial 
biogenesis is resveratrol, which is an activator of sirtuin 
SIRT1. Until now, resveratrol has only been included 
in a clinical trial of healthy elderly individuals (rather 
than mitochondrial disease patients), and increased 
mitochondrial function was observed (Libri et al., 2012). 
Finally, AICAR, which is an AMPK activator, was tested 
in human complex I-deficient fibroblasts and promising 
results were obtained, such as increased ATP levels and 
decreased ROS (Golubitzky et al., 2011). In summary, very 
detailed clinical trials are needed in order to determine the 
benefits of using mitochondrial biogenesis activators as 
new therapeutic agents.
In addition to ROS, other toxic substances such 
as hydrogen sulfide (H2S) are also the target of some 
potential treatments. It has been shown that NAC and 
metronidazole treatment is useful for ethylmalonic 
encephalopathy (Viscomi et al., 2010). Furthermore, 
targeting mitochondrial dynamics, autophagy, and 
mitochondrial membrane lipids are other possibilities that 
need to be investigated at the preclinical level (Andreux et 
al., 2013).
5.3. Gene therapy
Current treatment strategies are aimed at ameliorating 
symptoms and reducing the risk of complications. Cure 
and prevention of mtDNA-related diseases, however, 
requires more effective treatments. The primary goal for an 
effective gene therapy of mtDNA-related diseases is to alter 
the level of heteroplasmy, either by targeted degradation of 
mutant mtDNA or by blocking replication (Taylor et al., 
1997).
The earliest gene therapy trials, started in the late 
1990s, tested the potential of mitochondria-targeted 
peptide nucleic acid (PNA) oligomers, which are DNA-
like molecules with an aminoglycine backbone instead of 
phosphate ribose groups. In vitro assays showed that this 
technique could prevent replication of mutant mtDNA 
copies; however, cell line studies were less successful 
(Chinnery et al., 1999).
The next approach tried was to target mitochondrial 
genes with endonucleases. The m.8993T > G mutation 
is known to generate a specific SmaI endonuclease 
cleavage site. Therefore, delivery of SmaI to mitochondria 
containing the mutant mtDNA has the potential to deplete 
mutant mtDNA copies and result in biochemical rescue 
(Tanaka et al., 2002). Further advances in this field have 
been made possible by the use of chimeric zinc finger 
methylases (Minczuk et al., 2006). Use of specific zinc 
finger peptides (ZFPs) to target the m.8993T > G mutation 
resulted in reduction of heteroplasmy over a 30-day period 
(Minczuk et al., 2008). More recently, the development of 
transcription activator-like effectors (TALEs) and TALE 
nucleases (TALENs) has produced very promising results 
for mtDNA gene therapy (Boch et al., 2009; Hockemeyer 
et al., 2011). The use of TALENs resulted in reductions in 
heteroplasmy from 70% to 30% without affecting mtDNA 
copy number (Bacman et al., 2012). Supporting results have 
also been reported in a cybrid cell model of the common 
deletion (Gammage et al., 2014). Detailed analysis of these 
improvements are needed, and these techniques and their 
potential uses were critically evaluated in recent reviews 
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(Kaufmann et al., 2013; Moraes et al., 2014). Furthermore, 
it has been reported recently that the transmission of 
mtDNA mutations can be prevented in the germline by 
the use of TALENs to eliminate mutated mtDNA copies 
(Reddy et al., 2015). The same group also adapted the 
‘MitoTALENs’ technology, so they can be used by viral 
delivery vectors (Hashimoto et al., 2015). The common 
expectation in the field is to start testing this technology 
on patients who are waiting to be treated.
5.4. Genetic counseling
One of the most ideal strategies is to prevent mtDNA-
related disease before it occurs. Therefore, genetic 
counseling and prenatal diagnosis have started to be 
applied. Informing parents about the real risk of having 
a child with a mitochondrial disease should be done by 
professionals.  
Mechanism of transmission and segregation of mtDNA 
species (mutated and nonmutated) in the germline is not 
fully understood; therefore, prenatal genetic diagnosis 
resulted in limited success (Poulton et al., 2009). 
Although it is not possible to estimate heteroplasmy 
levels in individual tissues, and therefore not possible 
to predict clinical outcomes, prenatal genetic diagnosis 
has reportedly been applied successfully in several cases 
(Bouchet et al., 2006). Due to these uncertainties, parents 
are aiming to have offspring without any mutated mtDNA 
copies by the help of preimplantation genetic diagnosis 
(PGD) (Hellebrekers et al., 2012). 
6. Concluding remarks
Mitochondria are central to many processes in the cell, 
and disturbances to ATP metabolism trigger a wide range 
of symptoms. Increasing evidence has implicated mtDNA 
defects in numerous diseases such as LHON, MELAS, 
PEO, NARP, MILS, KSS, and Pearson syndrome and also 
in broader diseases such as neurodegeneration and cancer. 
A healthy mtDNA population is vital for the maintenance 
of efficient ATP production. However, further detailed 
research into the mechanisms of mtDNA-related diseases 
is required to develop effective diagnostic and treatment 
options. Recent advances in NGS discussed here will be 
particularly useful for effective diagnosis of patients. 
More detailed clinical trials incorporating mtDNA-related 
targets promise optimized pharmacological treatments in 
the coming years. Recent improvements in gene therapy are 
very promising, especially the use of TALENs, which has 
been successfully reported for the treatment of LHON and 
NARP. The first clinical trials of gene therapy are expected 
to start in the next few years. Global, multidisciplinary, 
and collaborative work on mtDNA-related diseases will be 
fundamental for the discovery of effective diagnostic and 
therapeutic strategies. 
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